Clinical trials: Disruptive Behavior Disorder
ADHD, Attention Deficit Hyperactivity Disorder
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
- Trial name
- NCT00585910
- Testing
- Atomoxetine and OROS Methylphenidate
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with…
- Trial name
- NCT02633527
- Testing
- 100mg SPN-812, 200mg SPN-812, 300mg SPN-812
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Attention Deficit Hyperactivity Disorder
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
This study looks to examine whether or not INTUNIV extended release can help children aged 6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving Executive Function when added to their usual care…
- Trial name
- NCT01985581
- Testing
- Guanfacine extended release, Stimulant therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- JPM van Stralen Medicine Professional
Conduct Disorder, Child
Virtual Reality to Improve Social Perspective Taking
This project will examine how virtual reality treatment that provides users with the alternate perspective of a virtual interpersonal interaction impacts psychological and neurobiological markers of social perspective taking in…
- Conditions
- Conduct Disorder, Child, Adolescent, Attention Deficit and Disruptive Behavior Disorders
- Trial name
- NCT03927612
- Testing
- Virtual reality perspective taking training, Virtual reality control perspective
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Indiana University
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit/Hyperactivity Disorder
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
- Trial name
- NCT04987762
- Testing
- Adhansia XR
- Where
- 15 sites in United States
- Volunteers
- 103 people
- Sponsor
- Purdue Pharma LP
Attention Deficit Disorder With Hyperactivity
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
- Trial name
- NCT00183391
- Testing
- Atomoxetine, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
ADHD, Parenting
Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial
This study will compare the effectiveness of combined parental stimulant medication and behavioral parent training (BPT) versus BPT alone on child ADHD-related impairment (primary outcome), child ADHD and externalizing symptoms…
- Trial name
- TPAC (NCT04240756)
- Testing
- Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- University of Maryland, College Park
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
ADHD
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
- Trial name
- NCT03172481
- Testing
- PRC-063 oral capsules
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Purdue Pharma, Canada
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03265119
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
ADHD
Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD
This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.
- Trial name
- NCT04167189
- Testing
- Lidocaine gel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- PhenoSolve, LLC
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Large-scale Brain Organization During Cognitive Control in ADHD
The purpose of this study is to test whether children with attention-deficit/hyperactivity disorder (ADHD) are impaired in the ability to flexibly adapt brain network organization in response to shifting cognitive demands during…
- Trial name
- NCT04349917
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of North Carolina, Chapel Hill
Attention-Deficit/Hyperactivity Disorder
Communication to Improve Shared Decision-Making in ADHD
The purpose of this study was to explore whether using an online patient portal plus a Care Manager is more effective than using an online portal alone in managing care for children with ADHD.
- Trial name
- ADHD-Link (NCT02716324)
- Testing
- Care Manager CM), ADHD Portal
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai